News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia
Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia...
Sunstone makes €5 million investment into Finnish women’s health company Forendo Pharma to finance clinical studies in endometriosis
Sunstone Life Science Ventures today announced its first investment out of its Life Science Ventures Fund IV into Forendo Pharma, a Finnish clinical stage drug development company focusing on novel treatments in women’s health. The investment is designated to finance...
Sunstone makes a non-revocable commitment to sell all shares in Nuevolution at a price of SEK 32.5 per share to Amgen, corresponding to SEK 332 million
Sunstone today announced that its Life Science Ventures Fund I has made a non-revocable commitment to sell all shares in Nuevolution AB at a price of SEK 32.5 per share. Nuevolution has been part of Sunstone’s portfolio since 2007 and Sunstone has played an active...
Trading in Ascelia Pharma’s shares on Nasdaq Stockholm commences tomorrow
Nasdaq Stockholm AB has today decided to admit the shares of Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) for trading on Nasdaq Stockholm with first day of trading tomorrow, Wednesday 13 March 2019. The shares will be traded under the ticker ACE and ISIN...
Ascelia Pharma’s new share issue in connection with the IPO on Nasdaq Stockholm was significantly oversubscribed
The offering in Ascelia Pharma AB (“Ascelia Pharma” or the “Company”) in connection with the Initial Public Offering on Nasdaq Stockholm was significantly oversubscribed. The new share issue (the “Offering”) will provide Ascelia Pharma with approximately SEK 200...
Arcoma: Omsättningen ökar 36%: fortsatta resultatförbättringar:
Arcomas kvartalsrapport för fjärde kvartalet 2018 – bokslutskommuniké – finns att läsa här Press inquiries should be adressed to: